Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Flowers Foods Q2 2026 slides: volume drop drives 19% EBITDA decline

Flowers Foods Q2 2026 slides: volume drop drives 19% EBITDA decline

Flowers Foods reported a decline in Q2 2026 results, driven by a drop in volume, which resulted in a 19% decrease in EBITDA. The company's net sales fell 4.0% year-over-year, with adjusted diluted earnings per share coming in at $0.21, below expectations of $0.24. The stock price experienced a 4.83% drop in regular trading and another 5.25% after hours, nearing its 52-week low.

CEO Ryals McMullian acknowledged the continued challenges in the fresh packaged bread category, citing pressure from household budgets, changing consumer behavior, and competitive activity. Net income for the quarter totaled $40.7 million, while adjusted EBITDA decreased 19.2% to $111.3 million, representing a margin of 9.3% of sales.

The company generated $241.5 million in operating cash flow to date and paid $81.0 million in dividends, investing $44.5 million in capital expenditures. To address the challenges, Flowers Foods outlined five strategic messages, including brand relaunch and innovation. The company plans to relaunch its Nature's Own brand with simpler ingredients, a first for a mainstream brand at national scale.

The relaunch includes updated packaging, a 360-degree marketing campaign featuring John Cena as The Breaducator, and a focus on small and half loaves, protein bread, sourdough, and breakfast bagels. Despite the near-term challenges, Flowers Foods remains committed to its long-term growth strategy, emphasizing brand investment and innovation.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.

  • iShares Pharma (IHE) focuses on established pharmaceutical companies
  • VanEck Biotech (BBH) targets high-growth biotechnology firms
  • BBH's beta is higher than IHE, indicating more volatility

More from Thursday 20 August →